Immuno-Biological Laboratories Co., Ltd. (4570.T)

JPY 458.0

(-2.35%)

Market Cap (In JPY)

4.26 Billion

Revenue (In JPY)

816.7 Million

Net Income (In JPY)

186.69 Million

Avg. Volume

121.42 Thousand

Currency
JPY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
358.0-649.0
PE
-
EPS
-
Beta Value
0.243
ISIN
JP3921300004
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Tsutomu Seito
Employee Count
-
Website
https://www.ibl-japan.co.jp
Ipo Date
2007-08-15
Details
Immuno-Biological Laboratories Co., Ltd. engages in the research, development, manufacturing, and supply of various immunological research reagents worldwide. The company offers ELILSA, an assay kit to quantitatively measure targeted substances; and support research services on Alzheimer's disease, metabolic syndrome, and cancer, as well as customized services for production of customized antibodies and development of ELISA systems. It also provides LipoSEARCH, a customized services for profiling and analyzing of lipoprotein through gel-filtration high performance liquid chromatography method that can profile various clinical samples, such as tiny plasma or serum samples from both small animals and human beings for broad range of research fields including lipid metabolism, development of drugs for life-style related diseases, development of functional supplemental foods, and clinical studies. In addition, the company offers LipoTEST, a support tool for diagnostic and health checks at animal clinics; and customized biomarker testing services for Life-style related diseases. Further, it operates protein production business using transgenic silkworms for manufacturing of antibodies for research reagents and diagnostic products; human collagen for cosmetic materials; development of proteins for use in drugs; and other proteins production. The company was incorporated in 1982 and is headquartered in Fujioka, Japan.